REGENCELL BIOSCIENCE HOLDING
RGCNASDAQTrading Snapshot
- Day Range
- $6.13 – $6.29
- 52-Week Range
- $4.51 – $69.00
- Volume
- $3.09B
- Avg Volume
- $3.91B
- Shares Outstanding
- 495.5M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $320M
- Last Q Revenue
- $83M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.01
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
Why Investors Own RGC
- ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
REGENCELL BIOSCIENCE HOLDING
RGC
StockOtter · stockotter.spaceAbout REGENCELL BIOSCIENCE HOLDING
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
RGC Resources, Inc. Declares Quarterly Dividend
ROANOKE, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock.
RGC Resources: More Likely To Appeal More To Income-Focused Investors
RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth
RGC Resources Q3 Earnings Call Highlights
RGC Resources NASDAQ: RGCO reported fiscal 2026 third-quarter net income of about $550,000, or $0.05 per diluted share, as higher margins supported results despite uneven weather patterns, increased operating expenses an
RGC Resources, Inc. Reports Third Quarter Earnings
ROANOKE, Va., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated earnings of $559,000, or $0.05 per diluted share, for the third quarter ended June 30, 2026, compared to $538,000,
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk